Skip to main content
Funded Studies

Daniela Berg, MD

Professor, Department for Neurodegenerative Diseases at Centre of Neurology and Hertie-Institute for Clinical Brain Research, University Hospital Tuebingen

Location: Tuebingen Germany

Daniela Berg, MD, received board certification as a neurologist in 2002 then worked until 2004 as a postdoctoral fellow at the Department of Human Genetics at the University Tübingen, followed by two years as senior resident in the Department of Neurology.

Since 2006 she has worked as senior physician at the University Hospital Tübingen, Department of Neurodegeneration. She leads the clinical neurodegeneration working group and is head of the outpatient clinic for parkinsonian syndromes, tremor and restless leg syndrome. Her main research interests comprise the early and differential diagnosis of neurodegenerative disorders, particularly the detection and validation of risk and biomarkers for diagnosis and progression of Parkinson’s disease and the characterization of specific endophenotypes for neurodegenerative disorders.

Since 2013 Prof. Berg has been president of the German Parkinson Society and medical director of the Centre of Outpatient Rehabilitation Tübingen, Department of Neurology. Together with Dr. Ron Postuma she chairs the Movement Disorder Society Task Force on the “Definition of Parkinson’s Disease” and is a member of the scientific advisory board of the German Parkinson’s Disease Association.


Associated Grants

  • Validation of the Movement Disorders Society’s Clinical Criteria of Parkinson’s Disease

    2014


  • Influence of Immune Subtypes on the LRRK2 Phenotype

    2013


  • Prospective Validation of Risk Markers for the Development of Parkinson’s Disease

    2010


  • Longitudinal Follow-Up of Clinical and Neuroimaging Signs and Biomarkers in Symptoms & Side Effects and aSymptoms & Side Effects LRRK2 Mutation Carriers in Comparison to Idiopathic PD and Controls

    2010


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.